openPR Logo
Press release

Hypertensive Emergency Medications Market Showcases Promising Growth during Forecast 2018-2028 // key player - Alvogen Inc., Baxter Laboratories Pty Ltd., NuCare Pharmaceuticals Inc., Pfizer Inc., Exela Pharma Sciences LLC

04-10-2019 09:38 AM CET | Health & Medicine

Press release from: Fact.MR

Hypertensive Emergency Medications Market Showcases

The growing prevalence of hypertension is expected to be a major factor driving the Hypertensive Emergency Medications Market over the forecast period. The rise in geriatric population is also boosting the market of hypertensive emergency medications. Unhealthy lifestyle is also contributing to the growing prevalence of various cardiovascular system disorders, which is also boosting the hypertensive emergency medications market.

Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=1298

Hypertensive emergency is the sudden elevation of blood pressure with signs of damage to the target organs such as the brain, kidneys and cardiovascular system. Hypertensive emergency medications are the immediate treatment required to reduce elevated blood pressure to prevent further damage to the organs. In a hypertensive emergency, acute organ damage has already occurred, and it requires blood reduction within one hour to prevent further damage to organs. Patients need effective medications to lower the elevated blood pressure and to protect target organ function. Neurologic end-organ damage due to hypertensive emergencies includes cerebral infarction, subarachnoid haemorrhage and others. Cardiovascular end-organ damage includes myocardial infarction, ventricular dysfunction, aortic dissection and others. With the advent of hypertensive emergency medications, the incidence of hypertension emergencies has decreased. Patients need rapidly acting medication administered intravenously to lower the elevated blood pressure.

The traditional drug for treating hypertensive emergency is sodium nitroprusside. The amount of dosage and the drug choice varies according to the type of disorder. Patients with acute myocardial infarction need to be treated with intravenous esmolol. There are several drugs to choose from for the management of hypertensive emergencies, which include nitroglycerin, labetalol, fenoldopam, nicardipine and clevidipine, among others. According to NCBI, total hypertensive emergencies have increased by 16.2% per year from 2006 to 2013.

Hypertensive Emergency Medications Market: Drivers and Restraints

The growing prevalence of hypertension is expected to be a major factor driving the hypertensive emergency medications market over the forecast period. The rise in geriatric population is also boosting the market of hypertensive emergency medications. Unhealthy lifestyle is also contributing to the growing prevalence of various cardiovascular system disorders, which is also boosting the hypertensive emergency medications market.

However, various adverse effects associated with the usage of drugs is hampering the growth of the hypertensive emergency medications market. Lack of awareness among individuals is also expected to restrain the growth of the hypertensive emergency medications market during the forecast period.

Browse Full Report with TOC- https://www.factmr.com/report/1298/hypertensive-emergency-medications-market

The global market for Hypertensive Emergency Medications is expected to grow at a significant rate over the forecast period. Effective management of hypertensive emergency requires careful considerations of aetiology and the indicated treatment. Nitroprusside has been one of the most commonly used hypertensive emergency medications because of its rapid onset and effectiveness. However, its usage has been decreasing owing to awareness about its level of toxicity. Nowadays, it is used in combination with other drugs to decrease the toxicity level. Several clinical studies have to be performed to improve the treatment and lower the adverse effects of hypertensive emergency medications. The intravenous route of drug administration is the most common form of administration for several drugs because of its rapid effect.

Hypertensive Emergency Medications Market: Regional Outlook

Geographically, the global hypertensive emergency medications market has been segmented into North America, Latin America, Europe, Asia-Pacific Excluding Japan (APEJ), Japan and the Middle East & Africa (MEA). North America is expected to be the dominant market in the global hypertensive emergency medications market owing to the high prevalence diseases and rise in geriatric population. In addition, a large number of key players offering hypertensive emergency medications are present in this region. Europe is expected to hold the second-largest share in the global hypertensive emergency medications market throughout the forecast period due to the availability of better healthcare facilities. The hypertensive emergency medications market in Asia Pacific is expected to grow at a significant CAGR due to rise in elderly population. However, Middle East and Africa is expected to register slower growth due to lack of awareness among individuals as well as poor healthcare facilities.

Hypertensive Emergency Medications Market: Key Players

The global market for hypertensive emergency medications is highly fragmented. Some of the key players operating in the global hypertensive emergency medications market are Alvogen, Inc.; Baxter Laboratories Pty Ltd.; NuCare Pharmaceuticals, Inc.; Pfizer Inc.; Exela Pharma Sciences LLC; Nexus Pharmaceuticals, Inc.; Novartis International AG and F. Hoffmann-La Roche AG.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=B&rep_id=1298

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypertensive Emergency Medications Market Showcases Promising Growth during Forecast 2018-2028 // key player - Alvogen Inc., Baxter Laboratories Pty Ltd., NuCare Pharmaceuticals Inc., Pfizer Inc., Exela Pharma Sciences LLC here

News-ID: 1696964 • Views:

More Releases from Fact.MR

Global SAP Cloud Platform Services Market is likely to reach a valuation of USD 6.5 Million by 2032
Global SAP Cloud Platform Services Market is likely to reach a valuation of USD …
Fact.MR recently conducted a study on the global SAP cloud platform services market is anticipated to surge from USD 443 million in 2022 to a staggering USD 7,000 million by 2032. This remarkable growth trajectory is projected to unfold at an exhilarating compound annual growth rate (CAGR) of 31% over the period spanning from 2022 to 2032. This analysis delves into pivotal trends shaping the market's growth trajectory. The report elucidates
Mobile Value Added Service Market is projected to rise at a CAGR of 14.9% through 2034
Mobile Value Added Service Market is projected to rise at a CAGR of 14.9% throug …
As per a recent study conducted by Fact.MR, a prominent provider of market research and competitive intelligence, the global Mobile Value Added Service Market is valued at approximately US$ 880.4 million in 2024. Forecasts indicate a robust compound annual growth rate (CAGR) of 14.9% through 2034, with the market anticipated to exceed a valuation of US$ 3,522.6 million by the end of that period. Intense competition among smartphone manufacturers has led
GMP Cell Banking Service Market value is projected to reach US$ 3,123.5 million by 2034
04-23-2024 | Health & Medicine
Fact.MR
GMP Cell Banking Service Market value is projected to reach US$ 3,123.5 million …
According to Fact.MR, a leading provider of market research and competitive intelligence, the global GMP Cell Banking Service Market is anticipated to reach approximately US$ 882.1 million by 2024. Over the period from 2024 to 2034, the market for GMP cell banking services is expected to witness a robust growth rate of 13.7%. The report further forecasts that the market will attain an overall valuation of US$ 3,123.5 million by
Global High Fiber Feed Market value is projected to reach US$ 524.1 million by 2034
04-23-2024 | Food & Beverage
Fact.MR
Global High Fiber Feed Market value is projected to reach US$ 524.1 million by 2 …
According to Fact.MR, a leading provider of market research and competitive intelligence, the High Fiber Feed Market achieved a value of approximately US$ 276.3 million in 2019. Projections suggest a notable growth trajectory, with demand expected to increase at a Compound Annual Growth Rate (CAGR) of 4.4% from 2024 to 2034. By 2034, the market is anticipated to reach US$ 524.1 million. The escalating global population and rising incomes have fueled

All 5 Releases


More Releases for Hypertensive

Anti-Hypertensive Drugs Market Size & Growth Analysis Report, 2020-2026
The global anti-hypertensive drugs market is anticipated to grow at a CAGR of over 4% during the forecast period. The anti-hypertensive drugs are used to restrict any complications of high blood pressure including myocardial infarction, stroke, and many more. In addition to this, anti-hypertensive drugs have their primary action on systemic vascular resistance and it also reduces systemic vascular resistance with long-term use. Moreover, hypertension is directly associated with increased
Anti-Hypertensive Drugs Market Size, Share and Forecast 2020-2026
The global anti-hypertensive drugs market is anticipated to grow at a CAGR of over 4% during the forecast period. The anti-hypertensive drugs are used to restrict any complications of high blood pressure including myocardial infarction, stroke, and many more. In addition to this, anti-hypertensive drugs have their primary action on systemic vascular resistance and it also reduces systemic vascular resistance with long-term use. Moreover, hypertension is directly associated with increased
Anti-Hypertensive Drugs Market Growth, Size, Share and Forecast 2020-2026
The global anti-hypertension drugs market is estimated to grow at a CAGR of over 4% during the forecast period. Hypertension is a common condition among patients with diabetes. Hence, the adoption of anti-hypertensive is high among the diabetic population for the treatment of hypertension. Hence, the increased diabetic population coupled with the adoption of anti-hypertensive drugs is anticipated to drive the anti-hypertensive drug market industry significantly. Additionally, Angiotensin-converting enzyme (ACE)
Global Hypertensive Heart Disease Market Research and Forecast, 2018-2023
Global hypertensive heart disease market, size, share, market intelligence, company profiles, market trends, strategy, research and analysis report by diagnosis (coronary angiography, chest x-ray, echo and electrocardiogram) forecast 2018-2023 “Increasing prevalence of heart disease is augmenting the growth of hypertensive heart disease market” According to OMR analysis, the global hypertensive heart diseases market is estimated to grow with a significant CAGR during the forecast period, 2018-2023. The rising prevalence of hypertensive
What's Behind the Rise of Anti-Hypertensive Drugs Market | Health
The global anti-hypertensive drugs market was valued at $32.2 billion in 2015, and is expected to reach $ 38.9 billion by 2022. Anti-hypertensive drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Thus the market is expected to grow at a CAGR of 2.73% from 2016 to 2022. Anti-hypertensive drugs are
Future of Anti-Hypertensive Drugs Market 2025: Sanofi, Lupin, AstraZeneca
HTF MI published a new industry research that focuses on Anti-Hypertensive Drugs market and delivers in-depth market analysis and future prospects of Global Anti-Hypertensive Drugs market. The study covers significant data which makes the research document a handy resource for managers, analysts, industry experts and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. The study is